Fig. 5: HSG4112 ameliorates fatty liver in HFD-induced obese mice orally administered with 100 mg kg−1 dose for 6 weeks (n = 10). | International Journal of Obesity

Fig. 5: HSG4112 ameliorates fatty liver in HFD-induced obese mice orally administered with 100 mg kg−1 dose for 6 weeks (n = 10).

From: Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity

Fig. 5

a Representative image of liver and its histological section stained with H&E. Standard bar = 200 µm. b Quantification of liver weight. NAS and fibrosis score on liver histology: c steatosis score, d lobular inflammation score, e NAS score, and f fibrosis score. Serum parameters associated with fatty liver: g triglyceride, h LDL cholesterol, i HDL cholesterol, j total cholesterol, k AST, and l ALT. All data represent terminal values of mean ± SEM. One-way ANOVA with Tukey’s multiple comparison test was performed; n.s. not significant, #p < 0.05, ###p < 0.001 vs. normal group, ***p < 0.001 vs. vehicle group.

Back to article page